Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1 - Pyridostigmine trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-010758-36-NL

Enrollment

Registered

2009-03-02

Start date

2009-05-19

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with CRPS-1.

Interventions

Trade Name: Mestinon Product Name: Pyridostigmine Product Code: N07AA02 Pharmaceutical Form: Tablet INN or Proposed INN: JP15/USP/INN CAS Number: 101-26-8 Current Sponsor code: D00487 Other descri

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CRPS-1 patients (Veldman criteria). Age > 18 jaar Standard treatment does not solve the complaints adequately. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: kydney failure other chronic pain syndromes parkinson's disease epilepsy asthma operations on the digestive tract in medical history active malignancy mental retardation

Design outcomes

Primary

Measure	Time frame
Secondary Objective: A secondary objective is an evaluation of possible improvement of clinical well being of the patients treated with Pyridostigmine. Side-effects of Pyridostigmine will be measured on a standardized scale. ;Primary end point(s): Improvement of functional status;Main Objective: The main objective of this trial is to evaluate the effect of Pyridostigmine (cholinesterase inhibitor) on inflammatory signs as pain, temperature, swelling and functional status of the extremity.	—

Measure

Time frame

Secondary Objective: A secondary objective is an evaluation of possible improvement of clinical well being of the patients treated with Pyridostigmine. Side-effects of Pyridostigmine will be measured on a standardized scale. ;Primary end point(s): Improvement of functional status;Main Objective: The main objective of this trial is to evaluate the effect of Pyridostigmine (cholinesterase inhibitor) on inflammatory signs as pain, temperature, swelling and functional status of the extremity.

—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026